고중성지방혈증을 동반한 제2형 당뇨병환자에서 ω-3 지방산과 Simvastatin 병합요법과 Simvastatin 단독요법의 지질 및 아포지단백 크기와 아형에 대한 비교 연구Effects of Adding ω-3 Fatty Acids to Simvastatin on Lipids, Lipoprotein Size and Subspecies in Type 2 Diabetes Mellitus with Hypertriglyceridemia
- Other Titles
- Effects of Adding ω-3 Fatty Acids to Simvastatin on Lipids, Lipoprotein Size and Subspecies in Type 2 Diabetes Mellitus with Hypertriglyceridemia
- Authors
- 김원준; 이창범; 박철영; 박세은; 이은정; 이원영; 오기원; 박성우; 김대중; 김혜진; 한승진; 조홍근
- Issue Date
- Dec-2009
- Publisher
- 대한당뇨병학회
- Keywords
- Fatty acids; Hypertriglyceridemia; Omega-3; Simvastatin; Type 2 diabetes mellitus
- Citation
- Diabetes and Metabolism Journal, v.33, no.6, pp.494 - 502
- Indexed
- KCI
- Journal Title
- Diabetes and Metabolism Journal
- Volume
- 33
- Number
- 6
- Start Page
- 494
- End Page
- 502
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/175637
- DOI
- 10.4093/kdj.2009.33.6.494
- ISSN
- 2233-6079
- Abstract
- Background: ω-3 fatty acids are known to improve lipid profiles, the distribution of lipoprotein subclasses, and secondary prevention against post-myocardial infarction. Rare reports have emerged of synergistic results of ω-3 fatty acids with simvastatin in cases of type 2 diabetes mellitus with hypertriglyceridemia. The purpose of this study was to determine the combined relationship of ω-3 fatty acids plus simvastatin on lipid, lipoprotein size and the types of subspecies.
Methods: This randomized, multi-center, comparison study evaluated eight weeks of combination therapy (ω-3 fatty acids (Omacor) 4 g/day plus simvastatin 20 mg/day) or monotherapy (simvastatin 20 mg/day) for at least six weeks in 62 diabetic patients. Subjects with a triglyceride concentration of more than 200 mg/dL were eligible for inclusion.
Results: No significant differences for ω-3 fatty acids + simvastatin versus simvastatin alone were observed for triglycerides (-22.7% vs. -14.3%, P = 0.292), HDL peak particle size (+2.8% vs. -0.4%, P = 0.076), LDL mean particle size (+0.4% vs -0.1%, P = 0.376) or LDL subspecies types, although the combination therapy showed a tendency toward lower triglycerides, larger HDL, and LDL particle sizes than did the monotherapy. There were no significant differences between the two groups in regard to HDL-C, LDL-C, or HbA1c levels. There were no serious adverse events and no abnormalities in the laboratory values associated with this study.
Conclusion: ω-3 fatty acids were a safeform of treatment in hypertriglyceridemic patients with type 2 diabetes mellitus. But, regarding efficacy, a much larger sample size and longer-term follow-up may be needed to distinguish between the effects of combination therapy and monotherapy.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.